


Pharmaceuticals & Biotechnology | Small Cap
Sigachi Industries demonstrates a mixed financial profile. The company exhibits strong solvency and profitability, indicating a solid foundation and efficient operations. Growth prospects are robust, driven by impressive revenue and asset expansion. However, efficiency metrics reveal challenges in asset utilization, particularly in fixed assets and working capital management. Liquidity is reasonably managed, though operating cash flow needs attention. Financial metrics such as EPS and capital expenditure scores are relatively low, suggesting areas for improvement in shareholder value and investment strategies. Overall, while the company shows considerable promise and strong financial health in some areas, there are operational inefficiencies that need to be addressed to ensure sustained success.
Sigachi Industries demonstrates a mixed financial profile. The company exhibits strong solvency and profitability, indicating a solid foundation and efficient operations. Growth prospects are robust, driven by impressive revenue and asset expansion. However, efficiency metrics reveal challenges in asset utilization, particularly in fixed assets and working capital management. Liquidity is reasonably managed, though operating cash flow needs attention. Financial metrics such as EPS and capital expenditure scores are relatively low, suggesting areas for improvement in shareholder value and investment strategies. Overall, while the company shows considerable promise and strong financial health in some areas, there are operational inefficiencies that need to be addressed to ensure sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-15.46
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
11.55
P/B RATIO
1.58
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
1.65
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.41
EV/EBITDA RATIO
6.03
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹21.03 as on Jun 15, 2026.
The company demonstrates strong growth in revenue, operating profit, assets, and net income. However, the negative EPS growth indicates potential challenges in translating growth into shareholder value. The company has a good growth in revenue and operating profit. The company has to work on its EPS growth so that shareholder value can be increased and maintained.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 29.53 | 20.8 | 32.12 | 22.31 | -2.05 |
| Operating Profit Growth Rate | 35.9 | 11.32 | 30.51 | 29.87 | -46 |
| Earnings Per Share (EPS) Growth | -67.01 | -100 | 4.6 | -217.58 | |
| Asset Growth Rate | 115.79 | 30.31 | 85.56 | 21.9 | -0.59 |
| Net Income Growth Rate | 33.33 | 10 | 29.55 | 22.81 | -218.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 34.88 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 75.74 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 26.69 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.76 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 40.63 | Neutral | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 17.07 | Undervalued | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 66.93 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 36.88 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | 11.55 | Highly Undervalued | 54.00 | -2.08 | -83.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 23.56 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 47.55 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 36.99 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -281.76 | Neutral | 187.00 | -1.50 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Concall Report⬤3rd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Annual Report⬤2nd Jul 26
Annual Report 2025-26
UNDEFINED SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT
Concall Report⬤2nd Jul 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT